Crystec applies the latest mSAS (modified supercritical anti-solvent) technologies to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical and biopharmaceutical industries, contributing to human health by enabling new and more effective therapies. Crystec SCF technologies can be applied to small and large drug molecules in a range of dosage forms. Our services include crystal form screening and particle design (including composite particles and co-crystals), addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management. Our process is scaled to GMP manufacturing levels. We are also engaged in in-house programmes to develop improved products and currently have licensing opportunities available in several therapeutic areas, including urge incontinence, fungal infections, and malaria. The first product based on SCF technology is expected to launch this year. It is an inhaled product for migraine - SCF processing enables exceptional particle size control and lung deposition resulting in rapid uptake. The particle design and scale-up to GMP for this product were managed by members of the Crystec team. Follow us on LinkedIn and Twitter
Miss Catherine HunterBusiness Development Director
Mr Paul ThorningCEO
East Midlands Business (Midlands Engine)
Mrs Louise StockHealthcare & Biotechnology Sector Specialist - Department for International Trade East Midlands
EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.